| Nov 12 |
Cogent Biosciences GAAP EPS of -$0.64 misses by $0.08
|
| Nov 5 |
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
|
| Oct 23 |
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
|
| Oct 20 |
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
|
| Oct 9 |
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target
|
| Sep 30 |
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
|
| Sep 3 |
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
|
| Aug 6 |
Cogent Biosciences GAAP EPS of -$0.59
|
| Aug 6 |
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
|
| Jun 27 |
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
|
